ACTRIMS 2023 | Serum proteins associated with glial cell injury, MRI measures & neuropsychological outcomes in MS

Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA, discusses a study aimed at determining the relationship between a multivariate, serum-derived proteomic data with future development of atrophied lesion volume (aLV) and leptomeningeal contrast enhancement (LMCE) in a heterogeneous group of approximately 200 patients with multiple sclerosis (MS) followed over five years. Findings showed that higher levels of glial fibrillary acidic protein (GFAP) and lower levels of myelin oligodendrocyte glycoprotein (MOG) were associated with greater accrual of aLV over the follow-up, suggesting that markers of glial activation are related to chronic lesional pathology and may be specific to the progressive MS phenotype. Additionally, an analysis of the serum proteomic associations with neuropsychological test outcomes in MS was performed. In this cohort of patients, the 9-Hole Peg Test, 25-Foot Walk Test, and Symbol Digit Modalities Test were strongly associated with disease progression defined based on the expanded disability status scale (EDSS). Several protein candidates representing diverse biological pathways were correlated with the worsening of neuropsychological test outcomes, including CXCL9, NfL, CDCP1, CCL20, and GFAP. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.